SITC 2024: Compugen's CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo
Anat Cohen-Dayag describes this SITC data, shares her opinion on the TIGIT field, and highlights an IL-18 program that is partnered with Gilead.